Abeona Therapeutics, Inc.
(NASDAQ : ABEO)

( )
ABEO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
ZTSZoetis, Inc. 0.22%130.401.9%$309.34m
TEVATeva Pharmaceutical Industries Ltd. 1.22%12.472.0%$157.68m
MYLMylan NV 3.20%16.143.2%$107.74m
BBIOBridgeBio Pharma, Inc. 0.91%35.320.0%$17.01m
RDYDr. Reddy's Laboratories Ltd. -0.93%50.932.0%$10.95m
TXMDTherapeuticsMD, Inc. 4.10%1.2722.1%$8.31m
ABEOAbeona Therapeutics, Inc. -5.57%3.054.5%$3.72m
TAROTaro Pharmaceutical Industries Ltd. 0.35%69.326.5%$2.20m
LFVNLifeVantage Corp. 0.88%14.883.3%$1.95m
COCPCocrystal Pharma, Inc. 0.00%1.010.0%$1.86m
KINKindred Biosciences, Inc. 8.81%5.190.3%$1.58m
JAGXJaguar Health, Inc. -0.23%0.432.0%$0.67m
CPHIChina Pharma Holdings, Inc. 1.68%0.470.1%$0.47m

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.